Create Free Account

By creating account you will get access to hot stocks & personalised emails

AFT Pharmaceuticals Ltd

Healthcare AU AFP

2.55AUD
-0.02(0.78%)

Last update at 2024-11-13T03:24:00Z

Day Range

2.552.57
LowHigh

52 Week Range

2.423.52
LowHigh

Fundamentals

  • Previous Close 2.57
  • Market Cap260.07M
  • Volume132
  • P/E Ratio17.71
  • Dividend Yield0.40%
  • EBITDA24.63M
  • Revenue TTM195.41M
  • Revenue Per Share TTM1.86
  • Gross Profit TTM 72.98M
  • Diluted EPS TTM0.14

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Income before tax 15.80M 18.68M 7.89M 12.88M -2.25900M
Minority interest - - - - -
Net income 10.65M 19.85M 7.78M 12.69M -3.36200M
Selling general administrative 11.12M 7.77M 7.78M 9.11M 7.20M
Selling and marketing expenses 38.28M 30.22M 28.90M 28.19M 28.21M
Gross profit 72.98M 61.77M 48.74M 48.27M 40.73M
Reconciled depreciation 1.72M 1.04M 1.10M 0.78M 0.32M
Ebit 19.67M 20.39M 10.71M 11.50M 6.64M
Ebitda 19.88M 20.67M 10.97M 11.77M 6.88M
Depreciation and amortization 0.21M 0.28M 0.26M 0.26M 0.24M
Non operating income net other - - - - -
Operating income 19.67M 20.39M 10.71M 11.50M 6.64M
Other operating expenses 137.98M 109.20M 101.78M 85.78M 82.03M
Interest expense 2.87M 2.44M 3.44M 8.05M 8.42M
Tax provision 5.14M -1.16300M 0.10M 0.18M 0.17M
Interest income 0.01M 0.00400M 0.00400M 5.57M 2.31M
Net interest income -2.86000M -2.43100M -3.43700M -8.03000M -8.37500M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 5.14M 1.16M 0.10M 0.18M 0.17M
Total revenue 156.64M 130.31M 113.11M 105.60M 85.13M
Total operating expenses 54.32M 40.66M 37.42M 28.45M 37.64M
Cost of revenue 83.66M 68.54M 64.36M 57.33M 44.40M
Total other income expense net -3.87000M -1.70400M -2.82100M 1.38M -8.89600M
Discontinued operations - - - - -
Net income from continuing ops 10.65M 19.85M 7.78M 12.69M -2.42700M
Net income applicable to common shares 10.65M 19.85M 7.59M 11.70M -3.36200M
Preferred stock and other adjustments - - - - -
Breakdown 2024-03-31 2023-03-31 2022-03-31 2021-03-31 2020-03-31
Type yearly yearly yearly yearly yearly
Date 2024-03-31 2023-03-31 2022-03-31 2021-03-31 2020-03-31
Total assets 165.26M 148.06M 121.76M 105.13M 87.05M
Intangible assets 53.46M 45.63M 38.09M 32.72M 26.98M
Earning assets - - - - -
Other current assets 0.41M 7.84M 6.24M 1.81M 3.86M
Total liab 77.46M 74.80M 65.02M 68.54M 69.80M
Total stockholder equity 87.80M 73.27M 56.74M 36.59M 17.25M
Deferred long term liab - 29.46M 22.11M 17.13M 11.52M
Other current liab 11.93M 17.59M 16.98M 17.40M 16.48M
Common stock 78.24M 78.24M 77.61M 77.20M 63.75M
Capital stock - 78.24M 77.61M 77.20M 63.75M
Retained earnings 9.26M -5.19800M -21.41600M -41.26400M -49.27500M
Other liab - - - 3.24M -
Good will - - - - -
Other assets - 33.93M 24.87M 17.86M 12.23M
Cash 12.04M 4.75M 7.94M 3.21M 6.12M
Cash and equivalents - - - - -
Total current liabilities 46.07M 39.77M 29.05M 32.10M 25.10M
Current deferred revenue - -3.02900M -4.54200M -5.77500M -2.50600M
Net debt 19.35M 33.30M 32.57M 39.01M 41.08M
Short term debt - 3.03M 4.54M 5.78M 2.51M
Short long term debt - 2.46M 4.00M 5.16M 2.00M
Short long term debt total 31.39M 38.05M 40.51M 42.22M 47.20M
Other stockholder equity - -2.94000M -2.61000M -2.50700M -10.79300M
Property plant equipment - 3.37M 3.36M 3.79M 4.03M
Total current assets 105.73M 94.60M 77.54M 67.90M 55.34M
Long term investments - - - - -
Net tangible assets - 57.10M 40.76M 21.00M -9.00000M
Short term investments - - - - -
Net receivables 44.22M 39.62M 29.87M 29.23M 22.63M
Long term debt - 32.20M 33.20M 33.20M 41.20M
Inventory 49.06M 42.40M 33.50M 33.65M 22.73M
Accounts payable 34.14M 22.18M 12.07M 14.70M 8.62M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.30M 0.23M 0.55M 0.66M 2.78M
Additional paid in capital - - - - -
Common stock total equity - - - 77.20M 63.75M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.25M -19.53300M -19.34800M -19.37400M -19.48900M
Deferred long term asset charges - - - - -
Non current assets total 59.53M 53.46M 44.22M 37.23M 31.72M
Capital lease obligations - 3.39M 3.31M 3.86M 4.00M
Long term debt total - - - 36.44M 44.70M
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Investments -9.17700M -5.58500M -6.23100M -6.56200M -1.41900M
Change to liabilities 12.67M -2.66300M 3.84M 5.88M -1.87900M
Total cashflows from investing activities -9.17700M -5.58500M -6.23100M -6.56200M -4.88400M
Net borrowings -4.59300M -2.01700M -5.49200M -2.65500M 7.42M
Total cash from financing activities -6.97800M -2.27600M 2.52M -9.11800M 3.72M
Change to operating activities - - - - -
Net income 10.65M 19.85M 7.78M 12.69M -2.42700M
Change in cash -4.64900M 4.73M -2.91000M -0.79700M 0.15M
Begin period cash flow 7.94M 3.21M 6.12M 6.92M 6.77M
End period cash flow 3.29M 7.94M 3.21M 6.12M 6.92M
Total cash from operating activities 11.63M 14.15M 0.75M 14.88M 1.07M
Issuance of capital stock 0.47M 0.29M 12.40M 0.00300M -
Depreciation 0.85M 0.91M 0.97M 0.96M 0.24M
Other cashflows from investing activities - - -6.23100M -6.23100M -6.23100M
Dividends paid - - 0.19M 0.57M 0.13M
Change to inventory -8.89700M 0.15M -10.92000M 2.42M -0.74600M
Change to account receivables -10.71600M -4.96300M -4.55600M -7.29700M -2.05400M
Sale purchase of stock - - -0.72300M 52.28M 60.32M
Other cashflows from financing activities -2.86000M 2.81M -2.46300M -0.51300M 3.86M
Change to netincome 6.20M 0.73M 3.50M 0.08M 7.85M
Capital expenditures 0.20M 0.33M 6.23M 6.56M 0.14M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -19.61300M -4.80900M -15.47600M -4.87200M -2.80000M
Stock based compensation - 0.01M 0.04M 0.11M -
Other non cash items 19.74M -6.60900M -8.00700M 1.23M 3.25M
Free cash flow 11.43M 13.82M -5.48100M 8.32M 0.93M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AFP
AFT Pharmaceuticals Ltd		 -0.02 0.78% 2.55 17.71 19.08 1.35 3.31 1.56 10.94
VLS
Vita Life Sciences Ltd		 - -% 2.09 12.06 - 1.46 2.42 1.15 6.64
LV1
Live Verdure Ltd		 0.03 4.29% 0.73 - - 52.75 39.01 42.66 -5.083
PER
Percheron Therapeutics Limited		 -0.003 3.53% 0.08 - - 27.59 8.75 347.00 -4.4641
VIT
Vitura Health Limited		 -0.003 3.06% 0.10 9.50 - 0.44 1.46 0.45 7.74

Reports Covered

Stock Research & News

View All

Profile

AFT Pharmaceuticals Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical products in New Zealand, Australia, Asia, and internationally. It offers products for use in the areas of allergy, gastrointestinal, cold and flu, digestive health, eye care, first aid, nail care, oral care, pain management, skin care, vitamins, and supplements, as well as other products. AFT Pharmaceuticals Limited was incorporated in 1997 and is headquartered in Auckland, New Zealand.

AFT Pharmaceuticals Ltd

129 Hurstmere Road, Auckland, New Zealand, 0622

Key Executives

Name Title Year Born
Dr. Hartley Atkinson Ph.D. Co-Founder, CEO, MD & Exec. Director NA
Ms. Marree Atkinson Co-Founder, Chief of Staff & Exec. Director NA
Mr. Malcolm Tubby B.A., BA(Hon's), ICAEW, ICANZ CFO & Company Sec. NA
Mr. Murray Keith Group Marketing Mang. NA
Ms. Ioana Stanescu Head of Drug Devel. NA
Mr. Calvin Mackenzie Gen. Mang. of AFT Australia NA
Mr. Scott Crawford Gen. Mang. of Promoted Products Australasia & South East Asia NA
Ms. Louise Clayton Director of International Bus. NA
Dr. Hartley Atkinson Ph.D. Co-Founder, CEO, MD & Executive Director NA
Ms. Marree Atkinson Co-Founder, Chief of Staff & Executive Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.